Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26:1604–20.
Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, et al. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: an International Collaborative Endorsement and Update of. J Thorac Oncol. 2020;15:1577–98. https://doi.org/10.1016/j.jtho.2020.06.021.
Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AKC, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655–64.
Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, et al. Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:439–51. https://doi.org/10.1016/j.annonc.2021.01.003.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60. https://doi.org/10.1097/JTO.0000000000000630.
Lococo F, Cesario A, Paci M, Filice A, Versari A, Rapicetta C, et al. PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids. Tumor Biol. 2014;35:8369–77.
Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151:193–203. https://doi.org/10.1016/j.chest.2016.10.010.
Benson REC, Rosado-de-Christenson ML, Martínez-Jiménez S, Kunin JR, Pettavel PP. Spectrum of pulmonary neuroendocrine proliferations and neoplasms. Radiographics. 2013;33:1631–49.
Lococo F, Perotti G, Cardillo G, De Waure C, Filice A, Graziano P, et al. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid. Clin Nucl Med. 2015;40:e183–9.
Purandare NC, Puranik A, Agrawal A, Shah S, Kumar R, Jiwnani S, et al. Does 68Ga-DOTA-NOC-PET/CT impact staging and therapeutic decision making in pulmonary carcinoid tumors? Nucl Med Commun. 2020;1040–6.
Papotti M, Croce S, Bellò M, Bongiovanni M, Allìa E, Schindler M, et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours: correlation with preoperative octreotide scintigraphy. Virchows Arch. 2001;439:787–97.
Righi L, Volante M, Tavaglione V, Billè A, Daniele L, Angusti T, et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 “clinically aggressive” cases. Ann Oncol. 2009;21:548–55.
Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi JC, et al. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med. 1990;31:1501–9.
Olsen JO, Pozderac RV, Hinkle G, Hill T, O’Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med. 1995;25:251–61.
Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, et al. Localization of neuroendocrine tumours with [111In]DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM Mon J Assoc Physicians. 1998;91:295–301.
Deroose CM, Hindié E, Kebebew E, Goichot B, Pacak K, Taïeb D, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57:1949–56.
Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, et al. The impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J Nucl Med. 2017;58:756–61.
Tirosh A, Kebebew E. The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. Futur Oncol. 2018;14:111–22.
Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, et al. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47:3033–46.
Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands—the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8:311–31.
Albanus DR, Apitzsch J, Erdem Z, Erdem O, Verburg FA, Behrendt FF, et al. Clinical value of 68Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET). Eur J Radiol. 2015;84:1866–72. https://doi.org/10.1016/j.ejrad.2015.06.024.
Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun. 2009;30:281–6.
Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga- DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50:1214–21.
Lou F, Sarkaria I, Pietanza C, Travis W, Roh MS, Sica G, et al. Recurrence of pulmonary carcinoid tumors after resection: Implications for postoperative surveillance. Ann Thorac Surg. 2013;96:1156–62. https://doi.org/10.1016/j.athoracsur.2013.05.047.
Öberg K, Hellman P, Ferolla P, Papotti M. Neuroendocrine bronchial and thymic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii120–3. https://doi.org/10.1093/annonc/mds267.
Pattenden HA, Leung M, Beddow E, Dusmet M, Nicholson AG, Shackcloth M, et al. Test performance of PET-CT for mediastinal lymph node staging of pulmonary carcinoid tumours. Thorax. 2015;70:379–81.
Jiang Y, Hou G, Cheng W. The utility of 18 F-FDG and 68 Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid 1–7.
Chan DL, Ulaner GA, Pattison D, Wyld D, Ladwa R, Kirchner J, et al. Dual PET imaging in bronchial neuroendocrine neoplasms: the NETPET score as a prognostic biomarker. J Nucl Med. 2021;62:1278–84.
Prinzi N, Rossi RE, Proto C, Leuzzi G, Raimondi A, Torchio M, et al. Recent advances in the management of typical and atypical lung carcinoids. Clin Lung Cancer. 2021;22:161–9.
Hofman MS, Hicks RJ. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. 2012;14:71–81.
Brown LM, Cooke DT, Jett JR, David EA. Extent of resection and lymph node assessment for clinical stage T1aN0M0 typical carcinoid tumors. Ann Thorac Surg. 2018;105:207–13. https://doi.org/10.1016/j.athoracsur.2017.07.049.
Rea F, Rizzardi G, Zuin A, Marulli G, Nicotra S, Bulf R, et al. Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. Eur J Cardio-thoracic Surg. 2007;31:186–91.
Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, et al. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol. 2016;26:900–9.
Lardinois D, De Leyn P, Van Schil P, Porta RR, Waller D, Passlick B, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardio-thoracic Surg. 2006;30:787–92.
Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Godstraw P. The IASLC lung cancer staging project : A proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568–77. https://doi.org/10.1097/JTO.0b013e3181a0d82e.
García-Yuste M, Matilla JM, Cueto A, Paniagua JMR, Ramos G, Cañizares MA, et al. Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardio-thoracic Surg. 2007;31:192–7.
Filosso PL, Guerrera F, Evangelista A, Welter S, Thomas P, Casado PM, et al. Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group. Eur J Cardio-thoracic Surg. 2015;48:441–7.
Senanayake R, Gillett D, MacFarlane J, Van de Meulen M, Powlson A, Koulouri O, et al. New types of localization methods for adrenocorticotropic hormone-dependent Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab. 2021;35:101513. https://doi.org/10.1016/j.beem.2021.101513.
Grigoryan S, Avram AM, Turcu AF, Lasing E, Arbor A, Arbor A. Functional imaging in ectopic cushing syndrome. Curr Opin Endocrinol Diabetes Obes. 2020;27:146–54.
Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50:1927–32.
Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112:2447–55.
Kumar A, Jindal T, Dutta R, Kumar R. Functional imaging in differentiating bronchial masses: an initial experience with a combination of 18F-FDG PET-CT scan and 68Ga DOTA-TOC PET-CT scan. Ann Nucl Med. 2009;23:745–51.
Jindal T, Kumar A, Venkitaraman B, Meena M, Kumar R, Malhotra A, et al. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging. 2011;11:70–5.
Venkitaraman B, Karunanithi S, Kumar A, Khilnani GC, Kumar R. Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2014;41:856–64.
Lococo F, Rapicetta C, Mengoli MC, Filice A, Paci M, Di Stefano T, et al. Diagnostic performances of 68Ga-DOTATOC versus 18Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumours and interrelationship with histological features. Interact Cardiovasc Thorac Surg. 2019;28:957–60.
Komek H, Can C, Urakçi Z, Kepenek F. Comparison of (18F)FDG PET/CT and (68Ga)DOTATATE PET/CT imaging methods in terms of detection of histological subtype and related SUVmax values in patients with pulmonary carcinoid tumors. Nucl Med Commun. 2019;40:517–24.
Cusumano G, Fournel L, Strano S, Damotte D, Charpentier MC, Galia A, et al. Surgical resection for pulmonary carcinoid: long-term results of multicentric study—the importance of pathological N status, more than we thought. Lung. 2017;195:789–98.
Daddi N, Schiavon M, Filosso PL, Cardillo G, Ambrogi MC, De Palma A, et al. Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids. Eur J Cardio-thoracic Surg. 2014;45:677–86.
Prasad V, Steffen IG, Pavel M, Denecke T, Tischer E, Apostolopoulou K, et al. Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids. EJNMMI Res. 2015. https://doi.org/10.1186/s13550-015-0130-2.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.